We are live on ! Find out more
VOR icon

Vor Biopharma
VOR

71 hedge funds and large institutions have $54.5M invested in Vor Biopharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

4% more funds holding

Funds holding: 68 → 71 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.33% less ownership

Funds ownership: 4.32% → 3.99% (-0.33%)

11% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 19

61% less capital invested

Capital invested by funds: $140M → $54.5M (-$85.2M)

Holders
71
Holders Change
+3
Holders Change %
+4.41%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
23
Increased
17
Reduced
19
Closed
20
Calls
$16K
Puts
–
Net Calls
+$16K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$456K
2
Millennium Management
Millennium Management
New York
+$374K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$357K
4
Jane Street
Jane Street
New York
+$328K
5
Renaissance Technologies
Renaissance Technologies
New York
+$260K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.83M
2
WP
Woodline Partners
California
-$2.63M
3
AG
Artal Group
Luxembourg
-$2.37M
4
LCM
Laurion Capital Management
New York
-$1.06M
5
State Street
State Street
Massachusetts
-$876K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
51
Virtu Financial
New York
$12K +$20K +619 New
JF
52
Jump Financial
Illinois
$11.3K +$18.3K +566 New
AQR Capital Management
53
AQR Capital Management
Connecticut
$11.2K +$18.1K +560 New
UBS Group
54
UBS Group
Switzerland
$11.2K -$44K -1,359 -71%
CFM
55
Catalyst Funds Management
Australia
$9.8K +$15.8K +490 New
Citigroup
56
Citigroup
New York
$6.46K -$1.71K -53 -14%
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
$5.5K -$61.7K -1,909 -87%
ProShare Advisors
58
ProShare Advisors
Maryland
$5.11K +$8.28K +256 New
Federated Hermes
59
Federated Hermes
Pennsylvania
$3.6K +$5.82K +180 New
Macquarie Group
60
Macquarie Group
Australia
$1.95K +$3.14K +97 New
Russell Investments Group
61
Russell Investments Group
United Kingdom
$1.23K +$2K +62 New
NS
62
NBC Securities
Alabama
$1K +$1.62K +50 New
JP Morgan Chase
63
JP Morgan Chase
New York
$983 -$24.6K -760 -94%
AAP
64
Arax Advisory Partners
Colorado
$528 +$841 +26 New
New York State Common Retirement Fund
65
New York State Common Retirement Fund
New York
$322 -$34.8K -1,077 -99%
Group One Trading
66
Group One Trading
Illinois
$229 -$5.17K -160 -94%
HI
67
Harbour Investments
Wisconsin
$200 – – –
EBA
68
Eagle Bay Advisors
New York
$150 – – –
SAM
69
Smartleaf Asset Management
Massachusetts
$116 +$162 +5 New
WP
70
Woodline Partners
California
– -$2.63M -55,556 Closed
AG
71
Artal Group
Luxembourg
– -$2.37M -50,000 Closed
Bank of New York Mellon
72
Bank of New York Mellon
New York
– -$248K -5,228 Closed
N
73
Nuveen
North Carolina
– -$169K -3,575 Closed
Deutsche Bank
74
Deutsche Bank
Germany
– -$75.4K -1,592 Closed
BCM
75
Bourgeon Capital Management
Connecticut
– -$69.8K -1,473 Closed
1 2
3
4

VOR Hedge Fund Activity: Q2 2024 in Review

71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2024, worth a combined $54.5M — down 61% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new VOR positions and 20 closed out — a net gain of 3 holders — while 17 added to existing stakes and 19 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $456K. The largest seller was BlackRock, cutting an estimated $2.83M.

  • 71 institutional investors held Vor Biopharma (VOR) as of Q2 2024, up from 68 in Q1 2024.
  • Funds reported $54.5M of Vor Biopharma stock for Q2 2024, down 61% quarter-over-quarter.
  • 23 funds opened new Vor Biopharma positions in Q2 2024 and 20 closed out, a net change of +3 holders.
  • The largest Vor Biopharma buyer in Q2 2024 was Goldman Sachs, an estimated $456K added.
  • The largest Vor Biopharma seller in Q2 2024 was BlackRock, an estimated $2.83M sold.

Based on aggregated 13F filings for Q2 2024.